Customer support

xie@china-sinoway.com
EnglishEnglish
What are you looking for?
banner
Solutions
Home Solutions

Anti-cancer drugs

Anti-cancer drugs

2020-03-24
Ten common anticancer drugs

1. Oxaliplatin: Researched and developed by the Swiss company Debiopharm. It is produced and sold by the French company Sanofi. It was first listed in France in October 1999, and then listed in Europe, South America and other places. my country approved the import of oxaliplatin injection in 1999. This product has a significant inhibitory effect on a variety of animal and human tumor cell lines such as colorectal cancer, non-small cell lung cancer, ovarian cancer and so on.

2. Vinorebine: also known as vinorelbine and norvinblastine, developed by the French company PierreFabre, listed in France in 1989, and listed in China in 1992. This product is a semi-synthetic fourth-generation Catharanthus alkaloid and a broad-spectrum anti-tumor drug.

3. Paclitaxel: A new plant anticancer drug developed by Bristol-Myers Bristol-Myers Bristol-Myers Bristol-Myers Squibb. It was first listed in the United States in October 1993, and the first domestic market was in 1995. The product mainly suppresses the important division of tumor cells (tubulin synthesis) to gradually reduce the tumor volume, rather than directly killing white blood cells.

4. Docetaxel: A new type of anti-tumor drug developed and produced by Sanofi-Aventis in France for the treatment of advanced breast cancer and non-small cell tumors. It was listed in Mexico for the first time in April 1995, and then listed in Britain, Italy, Germany, France, Japan, and the United States. It entered my country in 1996.

5. Gemcitabine: agreed to be used in China in December 1999. This drug is a new difluoronucleoside anti-metabolic and anti-cancer drug. It is a water-soluble analogue of deoxycytidine. It was originally developed for anti-virus. Now, the drug has been approved for the treatment of pancreatic cancer and non-small cell lung cancer, and research for the treatment of breast cancer, ovarian cancer, bladder cancer, prostate cancer, as well as leukemia and lymphoma is ongoing. This product has low toxicity, and its effect mechanism is relatively novel (the masking DNA chain stops and prevents DNA composition), and it is a promising combination chemotherapy drug.

6. Capecitabine: An oral fluoropyrimidine anti-tumor drug developed by Roche, which was launched in Switzerland and the United States in 1998, and is mainly used for the treatment of colorectal cancer.

7. Rituximab : Developed by Roche, it was listed in the UK in 1998. In 2001, its global sales volume reached 1.7 billion Swiss francs. This product is a recombinant chimeric anti-CD20 monoclonal antibody for refractory single-differentiated or follicular B-cell non-Hodgkin's lymphoma, marking the entry of monoclonal antibodies into the clinical treatment stage and pioneering the treatment of blood A new approach to systemic malignancies.

8. Hydroxycam pothecin: Developed by the Institute of Medicinal Plants of the Chinese Academy of Sciences, it was first marketed in China in 1996, and its production began in the 1970s. This drug is effective against a variety of malignant tumors. At present, it has a good effect in the treatment of leukemia and other tumors in addition to its application in digestive tract tumors, lung cancer, and reproductive system tumors.

9. Pirarubicin : developed by Meiji Seika Kaisha (Meiji Seika) Pharmaceutical Co., Ltd., listed in Japan in 1988, and listed in China in 1993. The anti-tumor activity of this product is equivalent to or slightly higher than that of doxorubicin, and it has a significant inhibitory effect on lung metastases. The clinical application shows that the drug has better curative effect on malignant lymphoma, acute leukemia, breast cancer, etc.; local arterial perfusion and intravesical administration have higher curative effect than whole body administration.

10. Epirubicin: Developed by an Italian company. In December 1984, it was listed in Italy for the first time, and it was listed in 1998 in China. Epirubicin is a replacement product of doxorubicin (doxorubicin). The difference between the two is the trans configuration of the C4 hydroxyl group in the amino sugar moiety of adriamycin. The bone marrow and cardiotoxicity of this drug are both higher than that of doxorubicin. Lower than the stars. Because this product has a high amount of hepatic eradication, after hepatic artery administration, its plasma eradication rate is also higher than that of intravenous administration, so it is mostly used for partial chemotherapy such as hepatic artery catheterization or intraperitoneal chemotherapy

Product categories

New Products

Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact